Compare Amgen, Inc. (AMGN) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Match Group Inc — how do they compare? Amgen, Inc. trades at $362.12 (market cap $196.12B), while Match Group Inc trades at $39.09 (market cap $9.06B). The key difference: Amgen, Inc. is far larger — about 21.6× Match Group Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | MTCH | |
|---|---|---|
Market Cap | $196.12B | $9.06B |
Sector | Health | Media |
52-Week High | $388.16 | $39.32 |
52-Week Low | $271.18 | $28.90 |
Enterprise Value | $241.41B | $12.01B |
Dividend Yield | 2.77% | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
MTCH trades at $38.85, down 1.2% today, with a bullish technical signal from moving averages and key support at $38. The company shows solid fundamentals with a P/E of 14.83, net income margin of 18.83%, and three consecutive quarterly earnings beats. Revenue growth remains stable at $3.49B for 2025, while cash flow from operations improved to $1.08B. Recent news highlights a turnaround focus, including Tinder's AI features and Hinge's growth.
The outlook is positive with a consensus price target of $41.63, implying 7% upside. Analyst sentiment is bullish (53% Buy), but risks include high long-term debt of $3.85B and competitive pressures in dating apps. Earnings growth and debt management are critical for sustained stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
